[Malignant rheumatoid arthritis].
Kobayashi
Shigeto
S
Department of Internal Medicine, Juntendo Koshigaya Hospital.
Kida
Issei
I
D001172:Arthritis, Rheumatoid / Q000175:diagnosis / Q000209:etiology / Q000473:pathology / Q000628:therapy; D001379:Azathioprine / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D006684:HLA-DR Antigens; D059811:HLA-DRB1 Chains; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008775:Methylprednisolone / Q000008:administration & dosage; D010951:Plasma Exchange; D011239:Prednisolone / Q000008:administration & dosage; D011379:Prognosis; D020551:Pulse Therapy, Drug; D012015:Reference Standards; D012217:Rheumatoid Factor; D012720:Severity of Illness Index
D006684:HLA-DR Antigens; D059811:HLA-DRB1 Chains; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D012217:Rheumatoid Factor; D011239:Prednisolone; D001379:Azathioprine; D008775:Methylprednisolone